Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features

It is still debated whether non-specific preclinical symptoms of Alzheimer’s disease (AD) can have diagnostic relevance. We followed the evolution from cognitively normal to AD by NMR-based metabolomics of blood sera. Multivariate statistical analysis of the NMR profiles yielded models that discrimi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Scientific reports 2020-09, Vol.10 (1), p.15612-15612, Article 15612
Hauptverfasser: Di Costanzo, Alfonso, Paris, Debora, Melck, Dominique, Angiolillo, Antonella, Corso, Gaetano, Maniscalco, Mauro, Motta, Andrea
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 15612
container_issue 1
container_start_page 15612
container_title Scientific reports
container_volume 10
creator Di Costanzo, Alfonso
Paris, Debora
Melck, Dominique
Angiolillo, Antonella
Corso, Gaetano
Maniscalco, Mauro
Motta, Andrea
description It is still debated whether non-specific preclinical symptoms of Alzheimer’s disease (AD) can have diagnostic relevance. We followed the evolution from cognitively normal to AD by NMR-based metabolomics of blood sera. Multivariate statistical analysis of the NMR profiles yielded models that discriminated subjective memory decline (SMD), mild cognitive impairment (MCI) and AD. We validated a panel of six statistically significant metabolites that predicted SMD, MCI and AD in a blind cohort with sensitivity values ranging from 88 to 95% and receiver operating characteristic values from 0.88 to 0.99. However, lower values of specificity, accuracy and precision were observed for the models involving SMD and MCI, which is in line with the pathological heterogeneity indicated by clinical data. This excludes a “linear” molecular evolution of the pathology, pointing to the presence of overlapping “gray-zones” due to the reciprocal interference of the intermediate stages. Yet, the clear difference observed in the metabolic pathways of each model suggests that pathway dysregulations could be investigated for diagnostic purposes.
doi_str_mv 10.1038/s41598-020-71832-y
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7515866</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2446665619</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-fd7cd5017c98b3079541558c670508890a3e071a43c6f05ae2d5a57602196e8a3</originalsourceid><addsrcrecordid>eNp9kctu1TAQhiNERavSF-gCeQebgC_xbYNUKm5SJTbt2vJxJue4OHHwJJUOT1_TU6qywQt75Pnm94z_pjln9D2jwnzAjklrWsppq5kRvN2_aE447WTLBecvn8XHzRniLa1Lctsx-6o5FtxqwbQ9afBTyrknm5hHX35CQRKnPga_AFl2fqkbkLlASHGqt4ng4reAJA_kIv3eQRyhvEXSRwSPDyTCtJB8ByX5eY7Tlow5QViTL2QAv6yVeN0cDT4hnD2ep83Nl8_Xl9_aqx9fv19eXLWh69TSDr0OvaRMB2s2gmor68jSBKWppMZY6gVQzXwnghqo9MB76aVWlDOrwHhx2nw86M7rZoQ-1M6KT24usc66d9lH929miju3zXdOSyaNUlXg3aNAyb9WwMWNEQOk5CfIKzpe-1RKKmYryg9oKBmxwPD0DKPuj2HuYJirhrkHw9y-Fr153uBTyV97KiAOANbUtIXibvNapvpp_5O9B8ZwpCg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2446665619</pqid></control><display><type>article</type><title>Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features</title><source>Nature Open Access</source><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><source>Springer Nature OA Free Journals</source><creator>Di Costanzo, Alfonso ; Paris, Debora ; Melck, Dominique ; Angiolillo, Antonella ; Corso, Gaetano ; Maniscalco, Mauro ; Motta, Andrea</creator><creatorcontrib>Di Costanzo, Alfonso ; Paris, Debora ; Melck, Dominique ; Angiolillo, Antonella ; Corso, Gaetano ; Maniscalco, Mauro ; Motta, Andrea</creatorcontrib><description>It is still debated whether non-specific preclinical symptoms of Alzheimer’s disease (AD) can have diagnostic relevance. We followed the evolution from cognitively normal to AD by NMR-based metabolomics of blood sera. Multivariate statistical analysis of the NMR profiles yielded models that discriminated subjective memory decline (SMD), mild cognitive impairment (MCI) and AD. We validated a panel of six statistically significant metabolites that predicted SMD, MCI and AD in a blind cohort with sensitivity values ranging from 88 to 95% and receiver operating characteristic values from 0.88 to 0.99. However, lower values of specificity, accuracy and precision were observed for the models involving SMD and MCI, which is in line with the pathological heterogeneity indicated by clinical data. This excludes a “linear” molecular evolution of the pathology, pointing to the presence of overlapping “gray-zones” due to the reciprocal interference of the intermediate stages. Yet, the clear difference observed in the metabolic pathways of each model suggests that pathway dysregulations could be investigated for diagnostic purposes.</description><identifier>ISSN: 2045-2322</identifier><identifier>EISSN: 2045-2322</identifier><identifier>DOI: 10.1038/s41598-020-71832-y</identifier><identifier>PMID: 32973179</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>692/4017 ; 692/53/2423 ; Aged ; Alzheimer Disease - blood ; Alzheimer Disease - classification ; Alzheimer Disease - pathology ; Biomarkers - blood ; Cognitive Dysfunction - blood ; Cognitive Dysfunction - pathology ; Disease Progression ; Female ; Humanities and Social Sciences ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; multidisciplinary ; ROC Curve ; Science ; Science (multidisciplinary)</subject><ispartof>Scientific reports, 2020-09, Vol.10 (1), p.15612-15612, Article 15612</ispartof><rights>The Author(s) 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-fd7cd5017c98b3079541558c670508890a3e071a43c6f05ae2d5a57602196e8a3</citedby><cites>FETCH-LOGICAL-c446t-fd7cd5017c98b3079541558c670508890a3e071a43c6f05ae2d5a57602196e8a3</cites><orcidid>0000-0002-8643-658X ; 0000-0001-6751-9921</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515866/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7515866/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,41096,42165,51551,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32973179$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Di Costanzo, Alfonso</creatorcontrib><creatorcontrib>Paris, Debora</creatorcontrib><creatorcontrib>Melck, Dominique</creatorcontrib><creatorcontrib>Angiolillo, Antonella</creatorcontrib><creatorcontrib>Corso, Gaetano</creatorcontrib><creatorcontrib>Maniscalco, Mauro</creatorcontrib><creatorcontrib>Motta, Andrea</creatorcontrib><title>Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features</title><title>Scientific reports</title><addtitle>Sci Rep</addtitle><addtitle>Sci Rep</addtitle><description>It is still debated whether non-specific preclinical symptoms of Alzheimer’s disease (AD) can have diagnostic relevance. We followed the evolution from cognitively normal to AD by NMR-based metabolomics of blood sera. Multivariate statistical analysis of the NMR profiles yielded models that discriminated subjective memory decline (SMD), mild cognitive impairment (MCI) and AD. We validated a panel of six statistically significant metabolites that predicted SMD, MCI and AD in a blind cohort with sensitivity values ranging from 88 to 95% and receiver operating characteristic values from 0.88 to 0.99. However, lower values of specificity, accuracy and precision were observed for the models involving SMD and MCI, which is in line with the pathological heterogeneity indicated by clinical data. This excludes a “linear” molecular evolution of the pathology, pointing to the presence of overlapping “gray-zones” due to the reciprocal interference of the intermediate stages. Yet, the clear difference observed in the metabolic pathways of each model suggests that pathway dysregulations could be investigated for diagnostic purposes.</description><subject>692/4017</subject><subject>692/53/2423</subject><subject>Aged</subject><subject>Alzheimer Disease - blood</subject><subject>Alzheimer Disease - classification</subject><subject>Alzheimer Disease - pathology</subject><subject>Biomarkers - blood</subject><subject>Cognitive Dysfunction - blood</subject><subject>Cognitive Dysfunction - pathology</subject><subject>Disease Progression</subject><subject>Female</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Middle Aged</subject><subject>multidisciplinary</subject><subject>ROC Curve</subject><subject>Science</subject><subject>Science (multidisciplinary)</subject><issn>2045-2322</issn><issn>2045-2322</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kctu1TAQhiNERavSF-gCeQebgC_xbYNUKm5SJTbt2vJxJue4OHHwJJUOT1_TU6qywQt75Pnm94z_pjln9D2jwnzAjklrWsppq5kRvN2_aE447WTLBecvn8XHzRniLa1Lctsx-6o5FtxqwbQ9afBTyrknm5hHX35CQRKnPga_AFl2fqkbkLlASHGqt4ng4reAJA_kIv3eQRyhvEXSRwSPDyTCtJB8ByX5eY7Tlow5QViTL2QAv6yVeN0cDT4hnD2ep83Nl8_Xl9_aqx9fv19eXLWh69TSDr0OvaRMB2s2gmor68jSBKWppMZY6gVQzXwnghqo9MB76aVWlDOrwHhx2nw86M7rZoQ-1M6KT24usc66d9lH929miju3zXdOSyaNUlXg3aNAyb9WwMWNEQOk5CfIKzpe-1RKKmYryg9oKBmxwPD0DKPuj2HuYJirhrkHw9y-Fr153uBTyV97KiAOANbUtIXibvNapvpp_5O9B8ZwpCg</recordid><startdate>20200924</startdate><enddate>20200924</enddate><creator>Di Costanzo, Alfonso</creator><creator>Paris, Debora</creator><creator>Melck, Dominique</creator><creator>Angiolillo, Antonella</creator><creator>Corso, Gaetano</creator><creator>Maniscalco, Mauro</creator><creator>Motta, Andrea</creator><general>Nature Publishing Group UK</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-8643-658X</orcidid><orcidid>https://orcid.org/0000-0001-6751-9921</orcidid></search><sort><creationdate>20200924</creationdate><title>Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features</title><author>Di Costanzo, Alfonso ; Paris, Debora ; Melck, Dominique ; Angiolillo, Antonella ; Corso, Gaetano ; Maniscalco, Mauro ; Motta, Andrea</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-fd7cd5017c98b3079541558c670508890a3e071a43c6f05ae2d5a57602196e8a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>692/4017</topic><topic>692/53/2423</topic><topic>Aged</topic><topic>Alzheimer Disease - blood</topic><topic>Alzheimer Disease - classification</topic><topic>Alzheimer Disease - pathology</topic><topic>Biomarkers - blood</topic><topic>Cognitive Dysfunction - blood</topic><topic>Cognitive Dysfunction - pathology</topic><topic>Disease Progression</topic><topic>Female</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Middle Aged</topic><topic>multidisciplinary</topic><topic>ROC Curve</topic><topic>Science</topic><topic>Science (multidisciplinary)</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Di Costanzo, Alfonso</creatorcontrib><creatorcontrib>Paris, Debora</creatorcontrib><creatorcontrib>Melck, Dominique</creatorcontrib><creatorcontrib>Angiolillo, Antonella</creatorcontrib><creatorcontrib>Corso, Gaetano</creatorcontrib><creatorcontrib>Maniscalco, Mauro</creatorcontrib><creatorcontrib>Motta, Andrea</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Scientific reports</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Di Costanzo, Alfonso</au><au>Paris, Debora</au><au>Melck, Dominique</au><au>Angiolillo, Antonella</au><au>Corso, Gaetano</au><au>Maniscalco, Mauro</au><au>Motta, Andrea</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features</atitle><jtitle>Scientific reports</jtitle><stitle>Sci Rep</stitle><addtitle>Sci Rep</addtitle><date>2020-09-24</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>15612</spage><epage>15612</epage><pages>15612-15612</pages><artnum>15612</artnum><issn>2045-2322</issn><eissn>2045-2322</eissn><abstract>It is still debated whether non-specific preclinical symptoms of Alzheimer’s disease (AD) can have diagnostic relevance. We followed the evolution from cognitively normal to AD by NMR-based metabolomics of blood sera. Multivariate statistical analysis of the NMR profiles yielded models that discriminated subjective memory decline (SMD), mild cognitive impairment (MCI) and AD. We validated a panel of six statistically significant metabolites that predicted SMD, MCI and AD in a blind cohort with sensitivity values ranging from 88 to 95% and receiver operating characteristic values from 0.88 to 0.99. However, lower values of specificity, accuracy and precision were observed for the models involving SMD and MCI, which is in line with the pathological heterogeneity indicated by clinical data. This excludes a “linear” molecular evolution of the pathology, pointing to the presence of overlapping “gray-zones” due to the reciprocal interference of the intermediate stages. Yet, the clear difference observed in the metabolic pathways of each model suggests that pathway dysregulations could be investigated for diagnostic purposes.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>32973179</pmid><doi>10.1038/s41598-020-71832-y</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0002-8643-658X</orcidid><orcidid>https://orcid.org/0000-0001-6751-9921</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2045-2322
ispartof Scientific reports, 2020-09, Vol.10 (1), p.15612-15612, Article 15612
issn 2045-2322
2045-2322
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7515866
source Nature Open Access; MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry; Springer Nature OA Free Journals
subjects 692/4017
692/53/2423
Aged
Alzheimer Disease - blood
Alzheimer Disease - classification
Alzheimer Disease - pathology
Biomarkers - blood
Cognitive Dysfunction - blood
Cognitive Dysfunction - pathology
Disease Progression
Female
Humanities and Social Sciences
Humans
Magnetic Resonance Imaging
Male
Middle Aged
multidisciplinary
ROC Curve
Science
Science (multidisciplinary)
title Blood biomarkers indicate that the preclinical stages of Alzheimer's disease present overlapping molecular features
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-15T03%3A43%3A47IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Blood%20biomarkers%20indicate%20that%20the%20preclinical%20stages%20of%20Alzheimer's%20disease%20present%20overlapping%20molecular%20features&rft.jtitle=Scientific%20reports&rft.au=Di%20Costanzo,%20Alfonso&rft.date=2020-09-24&rft.volume=10&rft.issue=1&rft.spage=15612&rft.epage=15612&rft.pages=15612-15612&rft.artnum=15612&rft.issn=2045-2322&rft.eissn=2045-2322&rft_id=info:doi/10.1038/s41598-020-71832-y&rft_dat=%3Cproquest_pubme%3E2446665619%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2446665619&rft_id=info:pmid/32973179&rfr_iscdi=true